Jane Hollingsworth J.D.

Non-Executive Director

Jane is the founding Managing Partner of Militia Hill Ventures (MHV), a US based organization that creates, builds and invests in life sciences companies.  While at MHV, Jane has co-founded and served as Executive Chair of Spirovant Sciences (formerly Talee Bio), a gene therapy company focused on cystic fibrosis and other pulmonary diseases, sold to Roivant Sciences in 2019 and then to Sumitomo Dainippon in 2020. Jane also served as Executive Chair and CEO of Immunome Inc., a cancer immunotherapy company.

Prior to MHV, Jane was co-founder and CEO of NuPathe Inc. (NASDAQ: PATH), a biopharmaceutical company focused on diseases of the central nervous system which was sold to Teva. She also co-founded and served as EVP of Auxilium Pharmaceuticals (NASDAQ: AUXL), a biopharmaceutical company focused on urology which was sold to Endo Pharmaceuticals.  Prior to founding and leading multiple biopharmaceutical companies, Ms. Hollingsworth was VP, Secretary & General Counsel of IBAH, Inc. (NASDAQ: IBAH), a multinational clinical research organization.

Jane practiced law at the Philadelphia law firm of Montgomery, McCracken, Walker & Rhoads and served as law clerk to the Honorable Jane R. Roth of the United States District Court for the District of Delaware.